A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment of Clostridium difficile infection (CDI).
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED STUDYTO COMPARE THE EFFICACY AND SAFETY OF RIDINILAZOLE (200 MG,BID) FOR 10 DAYS WITH VANCOMYCIN (125 MG, QID) FOR 10 DAYS INTHE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION (CDI).
A Phase I, 2-Part, Open-label, Multiple Oral Dose Study of the Safety, Tolerability and Pharmacokinetics of up to 2 Formulations of SMT C1100 in Healthy Adult Male Subjects and a Selected Formulation of SMT C1100 in Paediatric Subjects with Duchenne Muscular Dystrophy (DMD) - SMTC11004 - Phase 1 study in healthy volunteers and DMD patients
100 项与 Summit (Oxford) Ltd. 相关的临床结果
0 项与 Summit (Oxford) Ltd. 相关的专利（医药）
100 项与 Summit (Oxford) Ltd. 相关的药物交易
100 项与 Summit (Oxford) Ltd. 相关的转化医学
